Anti Cd 20 Ocrevus denied as not medically necessary by Aetna?

Aetna's specific coverage criteria for anti cd20 ocrevus are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denies Ocrevus on Medical-Necessity Grounds

A medical-necessity denial means Aetna's reviewer concluded the submitted records do not sufficiently demonstrate that Ocrevus (ocrelizumab) is required for this patient's specific clinical situation — as distinct from being merely preferable or convenient. For a high-cost specialty infusion like Ocrevus, Aetna typically requires documented evidence of MS subtype, disease activity or progression markers, and a clinical rationale explaining why this mechanism of action is appropriate now.

This is one of the most common denial types for DMTs and one of the most successfully reversed on appeal, because medical necessity is a clinical judgment call — and your neurologist's documented reasoning carries significant weight before an Independent Review Organization.

## Federal Appeal Rights

• Internal appeal: Under ERISA §503 or ACA rules, submit your internal appeal with additional clinical documentation. The denial letter will state the deadline — usually 180 days from the denial date.
• External review: If the internal appeal is denied, invoke ACA §2719 external review. A neutral IRO will evaluate whether the denial was consistent with generally accepted standards of medical practice, independent of Aetna's internal criteria.
• Expedited review: If your neurologist documents that waiting for a standard-track appeal creates serious health risk — for example, active relapse activity or rapid PPMS progression — request expedited processing.

## What to Gather

1. Diagnosis and disease-activity records — recent MRI reports (including comparison to prior studies to demonstrate new lesions or progression), EDSS or functional assessment scores, relapse history with dates, and neurologist clinic notes documenting current disease status. 2. Prior treatment history — complete list of DMTs previously tried, with start and stop dates and documented reasons for discontinuation (inadequate response, intolerance, contraindication). 3. Clinical severity documentation — anything in the chart quantifying disease burden: lesion load, relapses per year, functional decline trajectory. 4. Prescriber medical-necessity letter — your neurologist should state: MS subtype confirmed, disease activity documented, prior agents tried and why they are insufficient, and why Ocrevus is the medically necessary next step. Reference the applicable professional society guideline (AAN, National MS Society) without citing specific numeric thresholds. 5. Aetna's clinical policy bulletin — download it, identify each criterion, and check each one.

## Criteria-Mapping Structure

| Aetna Criterion (from policy bulletin) | Chart Evidence | |---|---| | Confirmed MS diagnosis with subtype | Neurology note + MRI report date | | Active disease or progression documented | MRI comparison; relapse log with dates | | Prior DMT history (if required) | Medication list with start/stop/reason | | Prescriber is appropriate specialist | Neurologist credentials/specialty noted | | Dose and schedule consistent with FDA label | Prescribing intent letter; confirm against label |

Every criterion Aetna used to deny must be addressed directly. If the denial letter lists specific reasons, quote them back and rebut each one with a page and date from the records.